Cansortium Inc.

CNSX:TIUM.U 주식 보고서

시가총액: US$45.3m

Cansortium 과거 수익 실적

과거 기준 확인 0/6

Cansortium has been growing earnings at an average annual rate of 15.3%, while the Pharmaceuticals industry saw earnings growing at 46% annually. Revenues have been growing at an average rate of 25.9% per year.

주요 정보

15.3%

수익 성장률

25.6%

EPS 성장률

Pharmaceuticals 산업 성장23.1%
매출 성장률25.9%
자기자본 수익률-230.1%
순이익-12.8%
최근 수익 업데이트30 Jun 2024

최근 과거 실적 업데이트

Recent updates

Cansortium (CSE:TIUM.U) Seems To Be Using A Lot Of Debt

Oct 25
Cansortium (CSE:TIUM.U) Seems To Be Using A Lot Of Debt

Cansortium Inc. (CSE:TIUM.U) Soars 30% But It's A Story Of Risk Vs Reward

Sep 04
Cansortium Inc. (CSE:TIUM.U) Soars 30% But It's A Story Of Risk Vs Reward

Cansortium Inc.'s (CSE:TIUM.U) CEO Compensation Is Looking A Bit Stretched At The Moment

Aug 21
Cansortium Inc.'s (CSE:TIUM.U) CEO Compensation Is Looking A Bit Stretched At The Moment

Slammed 32% Cansortium Inc. (CSE:TIUM.U) Screens Well Here But There Might Be A Catch

Jul 11
Slammed 32% Cansortium Inc. (CSE:TIUM.U) Screens Well Here But There Might Be A Catch

Cansortium Inc.'s (CSE:TIUM.U) Shares Not Telling The Full Story

Jan 15
Cansortium Inc.'s (CSE:TIUM.U) Shares Not Telling The Full Story

Is Cansortium (CSE:TIUM.U) Using Too Much Debt?

Nov 30
Is Cansortium (CSE:TIUM.U) Using Too Much Debt?

Is Cansortium (CSE:TIUM.U) Using Debt Sensibly?

Sep 01
Is Cansortium (CSE:TIUM.U) Using Debt Sensibly?

Cansortium Inc. (CSE:TIUM.U) Looks Inexpensive After Falling 30% But Perhaps Not Attractive Enough

Jul 28
Cansortium Inc. (CSE:TIUM.U) Looks Inexpensive After Falling 30% But Perhaps Not Attractive Enough

An Intrinsic Calculation For Cansortium Inc. (CSE:TIUM.U) Suggests It's 26% Undervalued

Mar 08
An Intrinsic Calculation For Cansortium Inc. (CSE:TIUM.U) Suggests It's 26% Undervalued

Does Cansortium (CSE:TIUM.U) Have A Healthy Balance Sheet?

Jan 09
Does Cansortium (CSE:TIUM.U) Have A Healthy Balance Sheet?

Here's Why Cansortium (CSE:TIUM.U) Has A Meaningful Debt Burden

Sep 09
Here's Why Cansortium (CSE:TIUM.U) Has A Meaningful Debt Burden

수익 및 비용 분석

Cansortium 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.


수익 및 매출 내역

CNSX:TIUM.U 수익, 비용 및 수입 (USD Millions )
날짜수익수익G+A 비용R&D 비용
30 Jun 24103-13360
31 Mar 24100-20340
31 Dec 2397-23310
30 Sep 2395-36290
30 Jun 2392-36280
31 Mar 2390-34260
31 Dec 2288-37260
30 Sep 2283-15270
30 Jun 2276-2270
31 Mar 2270-24270
31 Dec 2165-19300
30 Sep 2162-31320
30 Jun 2161-47330
31 Mar 2157-28350
31 Dec 2052-37320
30 Sep 2047-48350
30 Jun 2040-51350
31 Mar 2033-51350
31 Dec 1929-53410
30 Sep 1924-54410
30 Jun 1919-13390
31 Mar 1914-9330
31 Dec 1880210
30 Sep 18316140
30 Jun 180-1590
31 Mar 180-1680
31 Dec 170-1080

양질의 수익: TIUM.U is currently unprofitable.

이익 마진 증가: TIUM.U is currently unprofitable.


잉여현금흐름 대 수익 분석


과거 수익 성장 분석

수익추이: TIUM.U is unprofitable, but has reduced losses over the past 5 years at a rate of 15.3% per year.

성장 가속화: Unable to compare TIUM.U's earnings growth over the past year to its 5-year average as it is currently unprofitable

수익 대 산업: TIUM.U is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-40.8%).


자기자본 수익률

높은 ROE: TIUM.U has a negative Return on Equity (-230.12%), as it is currently unprofitable.


자산 수익률


고용 자본 수익률


과거 성과가 우수한 기업 찾기